2. Academic Validation
  3. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application

Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application

  • J Med Chem. 2019 Feb 28;62(4):1731-1760. doi: 10.1021/acs.jmedchem.8b01092.
Wei Yan 1,  Naga Rajiv Lakkaniga 1,  Francesca Carlomagno 2 3,  Massimo Santoro 2,  Neil Q McDonald 4 5,  Fengping Lv 1,  Naresh Gunaganti 1,  Brendan Frett 1,  Hong-Yu Li 1
Affiliations

Affiliations

  • 1 Department of Pharmaceutical Sciences, College of Pharmacy , University of Arkansas for Medical Sciences , Little Rock , Arkansas 72205 , United States.
  • 2 Dipartimento di Medicina Molecolare e Biotecnologie Mediche , Università Federico II , Via S Pansini 5 , 80131 Naples , Italy.
  • 3 Istituto di Endocrinologia e Oncologia Sperimentale del CNR , Via S Pansini 5 , 80131 Naples , Italy.
  • 4 Signaling and Structural Biology Laboratory , The Francis Crick Institute , London NW1 1AT , U.K.
  • 5 Institute of Structural and Molecular Biology, Department of Biological Sciences , Birkbeck College , Malet Street , London WC1E 7HX , U.K.
PMID: 30188734 DOI: 10.1021/acs.jmedchem.8b01092
Abstract

The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib. Annually, it is estimated that around ∼20 000 new cases of tropomyosin receptor kinase (Trk) cancers are diagnosed, with the majority of cases exhibiting a Trk genomic rearrangement. In this Perspective, we discuss current development and clinical applications for Trk precision medicine by providing the following: (1) the biological background and significance of the Trk kinase family, (2) a compilation of known Trk inhibitors and analysis of their cocrystal structures, (3) an overview of Trk clinical trials, and (4) future perspectives for drug discovery and development of Trk inhibitors.

Figures